Romidepsin (FK228, Depsipeptide)

製品コードS3020 別名:FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide)化学構造

分子量(MW):540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 26062.00
JPY 79182.00
JPY 115702.00

カスタマーフィードバック(4)

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
特性 More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
ターゲット
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外試験

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NFzpeGJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHP4[mgzNjVvMUWgcm0> M1zBd|czKGh? NW[wdYdZcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NF7GeHozPTd7MEmwOy=>
U2932  NXz0UHJWS2WubDDWbYFjcWyrdImgRZN{[Xl? NXjGPYhsOi53LUG1JI5O NWOzeWN5PzJiaB?= NVfh[I43cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= M4\4NFI2PzlyOUC3
OCI-LY7 Mnn5R4VtdCCYaXHibYxqfHliQYPzZZk> NWe2dJhWOi53LUG1JI5O NH7wWHQ4OiCq MljNbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? M4j3e|I2PzlyOUC3
Farage MmfrR4VtdCCYaXHibYxqfHliQYPzZZk> NFfGRVgzNjVvMUWgcm0> MX63NkBp NUTnNmhCcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NWHz[25OOjV5OUC5NFc>
LY7/EBV Mnm3R4VtdCCYaXHibYxqfHliQYPzZZk> MViyMlUuOTVibl2= NUP2eGR3PzJiaB?= NGHZTllqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NHq5UIozPTd7MEmwOy=>
U2932/EBV M3y3UmNmdGxiVnnhZoltcXS7IFHzd4F6 NYG4UldtOi53LUG1JI5O NHPjSpE4OiCq MonIbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NX;ke2hLOjV5OUC5NFc>
HCT116 NFTLUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWO1MVUxODBibl2= NFWzSWczPCCq NYnKNJlRTE2VTx?= MYTpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MkjiNlU1QTJ3MUW=
ACH-2 NYiwVXY4TnWwY4Tpc44hSXO|YYm= MVWxMVkhdk1? NVP3S2VqOjRiaB?= MV3pcoR2[2W|IFjJWk0yKEWwdjDlfJBz\XO|aX;u M4LxXlI2OTR7NE[3
MCF-10A MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7MUWRIUUN3ME2wMlE4yrFyLkCxJI5O M4fncFI1QTV2OEW2
MCF-7 MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rFeGlEPTB;MT6xNOKyOC5{MDDuUS=> NWL4eHl7OjR7NUS4OVY>
SK-BR-3 Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL0ZXRHUUN3ME2xMlAxyrFyLkO1JI5O MWGyOFk2PDh3Nh?=
MDA-MB-231 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfvUIYxUUN3ME2wMlY5yrFyLkG0JI5O NH;VOFEzPDl3NEi1Oi=>
PC3 NFyyT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwNkZCtVAvOzVibl2= NXXuXG44OjR7NUS4OVY>
HCT116 M1XMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFwMEFCtVAvODBibl2= M3HtblI1QTV2OEW2
HCT116-p21-/- NUfTfo17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{S5UmlEPTB;MT6yOuKyOC5|NzDuUS=> NW\HcVE1OjR7NUS4OVY>
S1 M{f0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW5eWxsUUN3ME23MlY4yrFyLkK5JI5O Ml3rNlQ6PTR6NU[=
SW620 M1XQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXHTWM2OD1yLkmzxtExNjJ7IH7N MoHwNlQ6PTR6NU[=
LOX-IMVI NULhOZFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O2WmlEPTB;MD64O:KyOC5yMzDuUS=> NEOwfYgzPDl3NEi1Oi=>
UACC-62 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fwOGlEPTB;MD61OuKyOC5zNjDuUS=> MWOyOFk2PDh3Nh?=
MDA-MB-435 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwOUFCtVAvODZibl2= MXKyOFk2PDh3Nh?=
SF-295 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fyWWlEPTB;MD64POKyOC5zNTDuUS=> M4i5eFI1QTV2OEW2
A549 MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jrWWlEPTB;MT6yOuKyOC5{NDDuUS=> NEjScVAzPDl3NEi1Oi=>
H460 M1zmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;YOpJIUUN3ME2yMlU5yrFyLkiwJI5O NIjMWIMzPDl3NEi1Oi=>
EKVX M3zGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwM{RCtVAvOzRibl2= MnXONlQ6PTR6NU[=
H146 NFTkeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMkNCtVAvODdibl2= M17QRlI1QTV2OEW2
H526 M3vkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfkUWdKSzVyPUCuNVXDuTBwMEOgcm0> NFzqNIszPDl3NEi1Oi=>
HuT-78 NYXqO2JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rncmlEPTB;MT63N:KyOC52NDDuUS=> M3;KdVI1QTV2OEW2
HA MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVSwMlYzPS1zMH7N M4DxTVQ5KGh? NHXHdHRqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? NWS5UXluOjR5N{G1NVA>
MS-275 NHTtSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGwMlYzPS1zMH7N MVy0PEBp MljmbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> NVjZWJlmOjR5N{G1NVA>
CD4 T NYnTeopiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPKU5VXPDhiaB?= NImwWFRGSzVyPUSuOeKyOS5yIH7N NWjKe3E4OjR5MkK0OVQ>
CD4 T MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO0OFghcA>? NFrkXZVESzVyPUGwO:KyOTJ4IH7N MnfvNlQ4OjJ2NUS=
CD4+ T M3zsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu2SWM2OD1|IH7N NXz4SoJLOjR2OUWxNFU>
A549 NYHPcXUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLWVFcyOOLCk{GwNOKhdk1? M1;GeFI1NzN4L{S4JIg> M2nkeolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NGTTWFczPDR6NUe5PS=>
JJN3 NXXxTmNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTHNlQwPDhiaB?= NGHlSnlGSzVyPEJihKlvVTtiNElihKlp MljJNlQxOzBzNUC=
OPM-2 M1\6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLlNlQwPDhiaB?= MWLFR|Uxez1z4pEJcm08KDR64pEJbC=> NF3tWGkzPDB|MEG1NC=>
RPMI-8226 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H2N|I1NzR6IHi= MVTFR|Uxez1zLklihKlvVTtiNElihKlp NFrpdm4zPDB|MEG1NC=>
U266 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmyOE81QCCq NYHER3B{TUN3MIO9NVDjiImwTUugOFjjiImq NEX4e3QzPDB|MEG1NC=>
CA46 MX7BdI9xfG:|aYOgRZN{[Xl? MXO2JIg> NGjOXYdqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= M4LsfVI{QTZ4MU[0
DG75 Mmf4RZBweHSxc3nzJGF{e2G7 NU[wNIk4PiCq M4HYc4lv\HWlZYOgco8h[XCxcITvd4l{ NGOwUlUzOzl4NkG2OC=>
Ramos M4HlXmFxd3C2b4Ppd{BCe3OjeR?= NXn6foI4PiCq NUDGTGpXcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ MWWyN|k3PjF4NB?=
ST486 M{jpfWFxd3C2b4Ppd{BCe3OjeR?= NF23V5I3KGh? Moj3bY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz NXHSS2RNOjN7Nk[xOlQ>
HuT78 Mn22RZBweHSxc3nzJGF{e2G7 Mo[0NU8yOC9zMECgcm0> M2TnVFQ5KGh? MU\pcoR2[2W|IHHwc5B1d3OrczDheEAyKG6P M3\4eVI{PTN{N{Oy
DpVp35 NHHGZXlCeG:ydH;zbZMhSXO|YYm= NF[0fZUyNzFyL{GwNEBvVQ>? M2HUXVQ5KGh? MoTRbY5lfWOnczDicJVvfCCjcH;weI9{cXN? MX:yN|U{Ojd|Mh?=
DpVp50 MY\BdI9xfG:|aYOgRZN{[Xl? NV3qeJdVOS9zMD:xNFAhdk1? M2HGVFQ5KGh? NXzXOWp7cW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NEiyO2UzOzV|MkezNi=>
DpP75  M3mxWWFxd3C2b4Ppd{BCe3OjeR?= NYTzeJlDOS9zMD:xNFAhdk1? NVTwUJczPDhiaB?= MUHpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? M{nlbVI{PTN{N{Oy
SKOV-3 NXK4NFB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6x5qCUOjCwTR?= NHWy[5c4OiCq NVPYPZNpTE2VTx?= NXjvTml5emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NXrreYNJOjNyMUCzOFg>
Brca1 WT NF7aWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfEcWY4OeLCk{Kwcm0> MnK1O|IhcA>? MonySG1UVw>? NGXiOVZz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NUfCPXBbOjNyMUCzOFg>
Brca1 Null M{THOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKx5qCUOjCwTR?= MXy3NkBp NHH6cFRFVVOR NYLZWIxCemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NWK3UFZCOjNyMUCzOFg>
OVCAR-8  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3WyelHjiJN{MH7N Mny2O|IhcA>? NYDPVXZqTE2VTx?= M3;HWpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NVPERoJvOjNyMUCzOFg>
NCI/ADR-RES MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOx5qCUOjCwTR?= NUeyT|hWPzJiaB?= M2LRfmROW09? MUfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> M3r6XFI{ODFyM{S4
HCT116 MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWi1JI5ONTVyIN88US=> M2C3UlI1KGh? MoLuSG1UVw>? MnvNbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> M2LadVIzQTJ2OUW4
RKO MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\POUBvVS13MDFOwG0> Mnf1NlQhcA>? MoLRSG1UVw>? MmC0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MnnsNlI6OjR7NUi=
CO115 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWC1JI5ONTVyIN88US=> MnO1NlQhcA>? NYHmeHBETE2VTx?= Mn\DbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MkjmNlI6OjR7NUi=
HFS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS1OUBvVQ>? MVSyOE81QC95MjDo M{S4SolvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> M33Hc|IzOTB4Mkiy
LNCaP MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfwfWY2KG6P NH;TToMzPC92OD:3NkBp MYPpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 NHrSOY0zOjFyNkK4Ni=>
A549 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;OPYE2KG6P Ml\hNlQwPDhxN{KgbC=> MYXpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 MmH2NlIyODZ{OEK=
697  MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|Ux6oDLPfMAjVIvPcLibl2= NX\wRlVDOjF3M{iyNVY>
697-R M1v3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:wTWM2OOLCiU5ihKk5NjcEoH7NxsA> NYfvNpBpOjF3M{iyNVY>
HUT78 M4fW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFibl2= NIfaT4QzOTF7OEW0OS=>
THJ-16T NGnyT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\HNUBvVQ>? NHH1VFAzPCCq M1vWW4lvcGmkaYTzJINmdGxiZ4Lve5Rp MmnDNlA5OTB3Nki=
HCT116 MWjGeY5kfGmxbjDBd5NigQ>? MlT6NlAhdk1? Mn;SPEBp MW\tc4R2dGG2ZYOgeJJidnOlcnnweEBt\X[nbIOg[o9zKGi3bnTy[YR{KG:oIHflcoV{KGmwIHXpeIhmeiCmaYLlZ5Rqd25? M1qxNFIxPzN7NEW0
B104  MUTGeY5kfGmxbjDBd5NigQ>? M1PSV|Ihdk1? NITYW5IzPC92OD:3NkBp NH76cXpqdmO{ZXHz[ZMhfGinIIP1doZi[2ViZYjwdoV{e2mxbjDv[kBETDJywrC= NFja[5czODZ6NkWwOS=>
HL-60  MmnNR5l1d3SxeHnjbZR6KEG|c3H5 M2ri[FEuPTByIH7N M1HlWlI1KGh? MUPpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh M3fGOlIxPjJ2MU[z
HP100 NXHWWI0{S3m2b4TvfIlkcXS7IFHzd4F6 MonGNU02ODBibl2= MVyyOEBp MYjpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NUfRZoRNOjB4MkSxOlM>
HL-60  NFnKVpVHfW6ldHnvckBCe3OjeR?= NVLTSW1MOTBibl2= NXSyNpRCPC94L{G2JIg> NX36NWtocW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo NGTJ[oQzODZ{NEG2Ny=>
HP100 M2fFc2Z2dmO2aX;uJGF{e2G7 MYCxNEBvVQ>? MX60M|YwOTZiaB?= MUTpcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? NXXK[2M1OjB4MkSxOlM>
HL-60  NYr0c5ZqTnWwY4Tpc44hSXO|YYm= MnfvNVAuPTByIH7N MlHVOEBp M{XjdIRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NYD2OXBqOjB4MkSxOlM>
HP100 MlzRSpVv[3Srb36gRZN{[Xl? NIq5dHMyOC13MECgcm0> NEPkPJk1KGh? M3TtfYRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NVP5XIprOjB4MkSxOlM>
11z NU\GOolGU2mwYYPlJGF{e2G7 MYezMVExOCCwTR?= MmLydoVlfWOnczDISGFEKGWweontZZRq[yCjY4Tpeol1gSBqSVO1NOKhRSB4LkWgxtEhOC54IH7tc4wwVCl? Mn;SNlA3ODVzNES=
SKOV-3 NUfTbINZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG4dJJsPC96L{G2JI5O MmTMOFghcA>? NVvqOHhCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MU[yNFQxPDV4NB?=
OVCAR-3 NXLFdGl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXTZnZjPC96L{G2JI5O NX;zdlNmPDhiaB?= NIj2dlNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NFvNd3UzODRyNEW2OC=>
HBL-2 NIDqSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C2flIuOTBibl2= NVe3TVdWOjRiaB?= NIrLcWVKSzVyPUSuN{BvVQ>? MnjSNlAxPjhyOEC=
Jeko-1 NHTndYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;GTXlMOi13MDDuUS=> NVr6WIlXOjRiaB?= M{C0OGlEPTB;MUGgcm0> MkHDNlAxPjhyOEC=
Granta-519 M4e1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWO1MVQxKG6P NUDVR2xyOjRiaB?= MVvJR|UxRTV6LkWgcm0> NIPHZlAzODB4OEC4NC=>
L1236 MnS3R5l1d3SxeHnjbZR6KEG|c3H5 M3HrTVEhdk1vMUCwJO69VQ>? NV\RVHJEPDhiaB?= M1LvTGVEPTB;MD6wO{DPxE1? M4nSXlE6OjN|NEew
L428 Mlj6R5l1d3SxeHnjbZR6KEG|c3H5 M3LPTFEhdk1vMUCwJO69VQ>? NEDEOVQ1QCCq NVfCSVJxTUN3ME2wMlQ{KM7:TR?= NFzi[2UyQTJ|M{S3NC=>
KM-H2 NXfvWFdrS3m2b4TvfIlkcXS7IFHzd4F6 MVSxJI5ONTFyMDFOwG0> MnLBOFghcA>? NF;TVnJGSzVyPUCuOVgh|ryP M1\5VVE6OjN|NEew
L540Cy Mlq4R5l1d3SxeHnjbZR6KEG|c3H5 NF3BbpAyKG6PLUGwNEDPxE1? MkOxOFghcA>? NUjyblMxTUN3ME2wMlE3KM7:TR?= NX3TSnM1OTl{M{O0O|A>
G401 MmrtSpVv[3Srb36gRZN{[Xl? MWGxNEBvVQ>? NWTSVXg5OjRxNEivO|IhcA>? NH63ZWVFVVOR MoH5bY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u M1Lu[VE6OjJzNUi2
STM91-01 NFzCO3lHfW6ldHnvckBCe3OjeR?= NYDiOJRNOTBibl2= MoLpNlQwPDhxN{KgbC=> MUfEUXNQ NFfBPVFqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> MoflNVkzOjF3OE[=
SJSC  NXTvXHBkTnWwY4Tpc44hSXO|YYm= MYqxNEBvVQ>? MViyOE81QC95MjDo Mke4SG1UVw>? M3LxNolv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> MVqxPVIzOTV6Nh?=
BT16  Mnj1SpVv[3Srb36gRZN{[Xl? MUGxNEBvVQ>? Ml;sNlQwPDhxN{KgbC=> MmXCSG1UVw>? NGrQblRqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> MXqxPVIzOTV6Nh?=
NCI-H1299 M1zLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTRwNtMxNE4zKG6pL33s NEPGPJAyQTF5OUi5NC=>
NCI-2882 NXjkPGJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXHOplKSzVyPUGuOuKyOC5yNDDu[{9udA>? NVHNfYRWOTlzN{m4PVA>
HCC95 M3;6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPwNHVlUUN3ME2yMlXDuTBwMEWgcocwdWx? MWixPVE4QTh7MB?=
NCI-H23 Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJwOdMxNE4zKG6pL33s NWq2TYYyOTlzN{m4PVA>
NCI-H157 NYjsbWI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLDTWM2OD1zLkdCtVAvODJibnevcYw> M4K4R|E6OTd7OEmw
NCI-H460 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHEfZBKSzVyPUKuNeKyOC5yNzDu[{9udA>? MoPrNVkyPzl6OUC=
NCI-H1975 M4rnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TMN2lEPTB;MT6zxtExNjB2IH7nM41t MVmxPVE4QTh7MB?=
NCI-H820 NF3GVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Xp[2lEPTB;Mj60xtExNjFibnevcYw> M2\YbVE6OTd7OEmw
NCI-H1650 M2jUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrCOnlrUUN3ME20MlnDuTBwMzDu[{9udA>? NGX5SmQyQTF5OUi5NC=>
DTC1 NWLv[JdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV60ZVZbUUN3ME2wMlUyKG6P MmrCNVg2PjZ{NE[=
KAO NH;xVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HQfmlEPTB;MD65NUBvVQ>? NF;qWlgyQDV4NkK0Oi=>
SU-CCS-1 NWGxbHRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fzVmlEPTB;MD64PUBvVQ>? MmjmNVg2PjZ{NE[=
SYO-1 M4D3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP6V4lNUUN3ME2wMlY4KG6P NG\sTIcyQDV4NkK0Oi=>
FUJI MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFwM{Ggcm0> Mln5NVg2PjZ{NE[=
SKNMC NXi4cZE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwMUegcm0> M4rxV|E5PTZ4MkS2
402-91 NWDlPZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIKw[5lKSzVyPUGuNlYhdk1? NUfwNIxwOTh3Nk[yOFY>
1765-92 M1OwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlflTWM2OD1zLke3JI5O NHTwblEyQDV4NkK0Oi=>
JN-DSRCT-1 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M335SmlEPTB;MT6yOUBvVQ>? MmL5NVg2PjZ{NE[=
NMS-2PC NFGzVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkKyTWM2OD1yLkixJI5O NH\WeI8yQDV4NkK0Oi=>
HL60 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzPeHZKSzVyPUGuPFYhdk1? M4nvb|E5PTZ4MkS2
A549 MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT0TWM2OD1|LkK0JI5O MlTPNVg2PjZ{NE[=
SW480 M1HMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzXVZpTUUN3ME2yMlY6KG6P M{fjelE5PTZ4MkS2
MCF7 NHTQfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W0b2lEPTB;Mz61OUBvVQ>? M3TSVFE5PTZ4MkS2
PC-3 NEjmfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfJeFJOUUN3ME2yMlUyKG6P MlXqNVg2PjZ{NE[=
MMRU MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\hfGlEPTB;Mj61O{BvVQ>? M33wTlE5PTZ4MkS2
Hs68 NF71c5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvSTWM2OD1-MUCgcm0> MXmxPFU3PjJ2Nh?=
hMSC-001F NGPZTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRT5zMDDuUS=> M1rZW|E5PTZ4MkS2

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
細胞試験:

[3]

+ 展開
  • 細胞株: HL60, Jurkat, A549, and MCF-7
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (参考用のみ)
動物試験:

[5]

+ 展開
  • 動物モデル: Male scid mice inoculated i.p. with U-937 cells
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~1 mg/kg once or twice a week
  • 投与方法: Treated i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 540.7
化学式

C24H36N4O6S2

CAS No. 128517-07-7
保管
in solvent
別名 FR 901228, NSC 630176

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01947140 Recruiting Lymphoid Malignancies|Multiple Myeloma|Lymphoma|Hodgkin Lymphoma|Non-hodgkin Lymphoma Jennifer Amengual|Columbia University September 9 2013 Phase 1|Phase 2
NCT02512497 Recruiting Cutaneous T-cell Lymphoma|T-Prolymphocytic Leukemia|T-Large Granulocytic Leukemia|T-Lymphoblastic Leukemia/Lymphoma|Peripheral T-Cell Lymphoma Ohio State University Comprehensive Cancer Center|Celgene Corporation December 8 2017 Phase 1
NCT00007345 Completed Cutaneous T Cell Lymphoma|Peripheral T Cell Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 8 2001 Phase 2
NCT00112463 Completed Adult Alveolar Soft-part Sarcoma|Adult Angiosarcoma|Adult Epithelioid Sarcoma|Adult Extraskeletal Chondrosarcoma|Adult Extraskeletal Osteosarcoma|Adult Fibrosarcoma|Adult Leiomyosarcoma|Adult Liposarcoma|Adult Malignant Fibrous Histiocytoma|Adult Malignant Hemangiopericytoma|Adult Malignant Mesenchymoma|Adult Neurofibrosarcoma|Adult Rhabdomyosarcoma|Adult Synovial Sarcoma|Gastrointestinal Stromal Tumor|Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Adult Soft Tissue Sarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma National Cancer Institute (NCI) January 7 2005 Phase 2
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital January 6 2017 Phase 2
NCT02181218 Recruiting Lymphoma T-Cell Cutaneous|Lymphoma T-Cell Peripheral|Hodgkin Disease|Lymphoma Large B-Cell Diffuse Washington University School of Medicine|Celgene February 4 2015 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Romidepsin (FK228, Depsipeptide)を買う | Romidepsin (FK228, Depsipeptide) ic50 | Romidepsin (FK228, Depsipeptide)供給者 | Romidepsin (FK228, Depsipeptide)を購入する | Romidepsin (FK228, Depsipeptide)費用 | Romidepsin (FK228, Depsipeptide)生産者 | オーダーRomidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)化学構造 | Romidepsin (FK228, Depsipeptide)分子量 | Romidepsin (FK228, Depsipeptide)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID